Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies

Maria Silvia Cona(Luigi Sacco Hospital), Massimo Di Nicola(Fondazione IRCCS Istituto Nazionale dei Tumori), Diego Signorelli(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Paolo Verderio(Fondazione IRCCS Istituto Nazionale dei Tumori), Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Sara Cresta(Fondazione IRCCS Istituto Nazionale dei Tumori), Mara Lecchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Daniele Raggi(Fondazione IRCCS Istituto Nazionale dei Tumori), Giovanni Randon(Fondazione IRCCS Istituto Nazionale dei Tumori), Silvia Damian(Fondazione IRCCS Istituto Nazionale dei Tumori), Andrea Necchi(Vita-Salute San Raffaele University), Raffaele Ratta(Fondazione IRCCS Istituto Nazionale dei Tumori), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), M. Poggi(Fondazione IRCCS Istituto Nazionale dei Tumori), Filippo de Braud(University of Milan)
Cancers
February 14, 2019
10.3390/cancers11020223
Cited by 30

Related Papers

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k